New hope for Triple-Negative breast cancer: which drug combo works best before surgery?
NCT ID NCT04138719
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This study tests two different chemotherapy combinations (nab-paclitaxel plus carboplatin vs. nab-paclitaxel plus epirubicin) given before surgery to shrink tumors in people with triple-negative breast cancer. The goal is to see which combo works better at eliminating cancer cells and making breast-conserving surgery possible. About 520 women aged 18-70 with tumors larger than 2 cm will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.